文献速递儿童青少年精神心境障碍焦虑、强迫与应激相关障碍

儿童青少年精神障碍药物、心理社会及脑刺激干预的疗效与可接受性:伞形综述

Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review.
PubMed 文献 · World Psychiatry · 2021-01-01

该伞形综述系统检索了儿童青少年精神障碍的网状Meta分析与Meta分析,涵盖48种药物、20种心理社会干预和4种脑刺激技术。共纳入14项网状Meta分析和90项Meta分析,涉及15种精神障碍。结果显示21种药物在共同主要结局上优于安慰剂,3种心理社会干预优于对照,为临床决策提供循证依据。

要点

  • 注意缺陷多动障碍中安非他明和哌甲酯疗效证据最充分,行为治疗次之。
  • 孤独症中阿立哌唑、利培酮及多种心理社会干预显示疗效。
  • 抑郁症中氟西汀、氟西汀联合认知行为疗法及人际心理治疗有效。

核心结论

  • 伞形综述汇总的Meta分析证据支持多种药物和心理社会干预用于儿童青少年精神障碍,其中21种药物在共同主要结局上优于安慰剂。

研究设计与样本

  • 伞形综述系统检索了随机对照试验的网状Meta分析和Meta分析,评估48种药物、20种心理社会干预和4种脑刺激技术,共纳入14项网状Meta分析和90项Meta分析。

主要发现

  • 共报告15种精神障碍或障碍组,21种药物在疾病特异性症状减少和全因停药率上优于安慰剂,3种心理社会干预在共同主要结局上优于对照。
  • 注意缺陷多动障碍中安非他明、哌甲酯和行為治療显示最令人信服的疗效特征。
  • 孤独症中阿立哌唑、利培酮和多种心理社会干预有效;破坏性行为障碍中利培酮和行为干预有效。
  • 精神分裂症谱系障碍中多种抗精神病药有效;抑郁症中氟西汀、氟西汀联合认知行为疗法和人际心理治疗有效。
  • 焦虑障碍中氟西汀和团体认知行为疗法有效;强迫症中氟西汀/选择性5-羟色胺再摄取抑制剂、认知行为疗法及暴露反应预防行为治疗有效。

关键数值与推荐

  • 共同主要结局为疾病特异性症状减少和全因停药(可接受性)。
  • 双相躁狂中阿立哌唑有效;创伤后应激障碍中认知行为疗法有效。
  • 遗尿症中丙咪嗪和警报行为干预有效;大便失禁中行为治疗有效;神经性厌食中家庭治疗有效。

临床怎么用

  • 该伞形综述结果为儿童青少年精神障碍的临床决策提供了循证信息,可指导药物和心理社会干预的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Top-tier evidence on the safety/tolerability of 80 medications in children/adolescents with mental disorders has recently been reviewed in this jour-nal. To guide clinical practice, such data must be combined with evidence on efficacy and acceptability. Besides medications, psychosocial inter-ventions and brain stimulation techniques are treatment options for children/adolescents with mental disorders. For this umbrella review, we systematically searched network meta-analyses (NMAs) and meta-analyses (MAs) of randomized controlled trials (RCTs) evaluating 48 medications, 20 psychosocial interventions, and four brain stimulation techniques in children/adolescents with 52 different mental disorders or groups of mental disorders, reporting on 20 different efficacy/acceptability outcomes. Co-primary outcomes were disease-specific symptom reduction and all-cause discontinuation ("acceptability"). We included 14 NMAs and 90 MAs, reporting on 15 mental disorders or groups of mental disorders. Overall, 21 medications outperformed placebo regarding the co-primary outcomes, and three psychosocial interventions did so (while seven outperformed waiting list/no treatment). Based on the meta-analytic evidence, the most convincing efficacy profile emerged for amphetamines, methylphenidate and, to a smaller extent, behavioral therapy in attention-deficit/hyperactivity disorder; aripiprazole, risperidone and several psychosocial interventions in autism; risperidone and behavioral interventions in disruptive behavior disorders; several antipsychotics in schizophrenia spectrum disorders; fluoxetine, the combination of fluoxetine and cognitive behavioral therapy (CBT), and interpersonal therapy in depression; aripiprazole in mania; fluoxetine and group CBT in anxiety disorders; fluoxetine/selective serotonin reuptake inhibitors, CBT, and behavioral therapy with exposure and response prevention in obsessive-compulsive disorder; CBT in post-traumatic stress disorder; imipramine and alarm behavioral intervention in enuresis; behavioral therapy in encopresis; and family therapy in anorexia nervosa. Results from this umbrella review of interventions for mental disorders in children/adolescents provide evidence-based information for clinical decision making.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Correll CU, Cortese S, Croatto G, et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. 2021. PMID: 34002501. doi:10.1002/wps.20881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。